AU2002219229A1 - Means for the diagnosis and therapy of CTCL - Google Patents

Means for the diagnosis and therapy of CTCL

Info

Publication number: AU2002219229A1
Authority: AU; Australia
Prior art keywords: ctcl; diagnosis; therapy
Prior art date: 2000-12-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

AU2002219229A

Other versions

AU2002219229B2 (en

AU2002219229B9 (en

Inventor

Martine Bagot

Armand Bensussan

Laurence Boumselle

Allessandro Moretta

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Institut National de la Sante et de la Recherche Medicale INSERM

Original Assignee

Institut National de la Sante et de la Recherche Medicale INSERM

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-18

Filing date

2001-12-18

Publication date

2002-09-05

2001-12-18 Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM

2001-12-18 Priority claimed from PCT/EP2001/015417 external-priority patent/WO2002050122A2/en

2002-07-01 Application granted granted Critical

2002-07-01 Publication of AU2002219229B9 publication Critical patent/AU2002219229B9/en

2002-09-05 Publication of AU2002219229A1 publication Critical patent/AU2002219229A1/en

2007-12-20 Publication of AU2002219229B2 publication Critical patent/AU2002219229B2/en

2021-12-18 Anticipated expiration legal-status Critical

Status Expired legal-status Critical Current

Links

AU2002219229A 2000-12-18 2001-12-18 Means for the diagnosis and therapy of CTCL Expired AU2002219229B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP00403580.4		2000-12-18
EP00403580		2000-12-18
PCT/EP2001/015417 WO2002050122A2 (en)	2000-12-18	2001-12-18	Means for the diagnosis and therapy of ctcl

Publications (3)

Publication Number	Publication Date
AU2002219229B9 AU2002219229B9 (en)	2002-07-01
AU2002219229A1 true AU2002219229A1 (en)	2002-09-05
AU2002219229B2 AU2002219229B2 (en)	2007-12-20

Family

ID=8173990

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AU1922902A Pending AU1922902A (en)	2000-12-18	2001-12-18	Novel means for the diagnosis and therapy of CTCL
AU2002219229A Expired AU2002219229B2 (en)	2000-12-18	2001-12-18	Means for the diagnosis and therapy of CTCL

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AU1922902A Pending AU1922902A (en)	2000-12-18	2001-12-18	Novel means for the diagnosis and therapy of CTCL

Country Status (9)

Country	Link
US (4)	US7399595B2 (en)
EP (1)	EP1343822B1 (en)
JP (3)	JP2004528824A (en)
AT (1)	ATE556092T1 (en)
AU (2)	AU1922902A (en)
CA (1)	CA2432036C (en)
DK (1)	DK1343822T3 (en)
ES (1)	ES2387969T3 (en)
WO (1)	WO2002050122A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1922902A (en) *	2000-12-18	2002-07-01	Inst Nat Sante Rech Med	Novel means for the diagnosis and therapy of CTCL
LT1648507T (en)	2003-07-24	2017-04-25	Innate Pharma S.A.	Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
WO2006016276A2 (en)	2004-08-03	2006-02-16	Innate Pharma S.A.	Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
EP3026063A1 (en) *	2004-12-28	2016-06-01	Innate Pharma S.A.	Monoclonal antibodies against nkg2a
CN101300272B (en) *	2005-10-14	2013-09-18	依奈特制药公司	Compositions and methods for treating proliferative disorders
NO346945B1 (en)	2006-06-30	2023-03-13	Novo Nordisk As	Anti-NKG2A antibodies and uses thereof
US7917085B2 (en) *	2007-11-09	2011-03-29	Research In Motion Limited	System and method for blocking devices from a carrier network
RU2010133892A (en)	2008-01-24	2012-02-27	Ново Нордиск А/С (DK)	HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN NKG2A
WO2009126804A2 (en) *	2008-04-11	2009-10-15	The Regents Of The University Of Colorado, A Body Corporate	Expression of kir in human cancer cells as a biomarker for immuno-escape and cancer metastasis
ES2539045T3 (en)	2009-01-19	2015-06-25	Innate Pharma	Anti-KIR3D antibodies
WO2011086179A1 (en)	2010-01-15	2011-07-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosis and treatment of cutaneous t cell lymphomas
WO2012164334A1 (en)	2011-05-31	2012-12-06	Indian Institute Of Technology Madras	Electrode and/or capacitor formation
CN103635487B (en)	2011-06-17	2016-10-12	诺沃—诺迪斯克有限公司	Selective elimination of erosive cells
US9024609B2 (en) *	2012-07-11	2015-05-05	Pai Capital Llc	Circuit and method for providing hold-up time in a DC-DC converter
AU2013320360B2 (en)	2012-09-19	2018-06-14	Innate Pharma	KIR3DL2 binding agents
US10246510B2 (en)	2012-09-19	2019-04-02	Innate Pharma	KIR3DL2 binding agents
WO2014107663A2 (en) *	2013-01-07	2014-07-10	The Trustees Of The University Of Pennsylvania	Compositions and methods for treating cutaneous t cell lymphoma
WO2014124267A1 (en) *	2013-02-07	2014-08-14	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
US20160002345A1 (en) *	2013-02-20	2016-01-07	Innate Pharma	A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
US20160108122A1 (en) *	2013-05-23	2016-04-21	Idac Theranostics, Inc.	Therapeutic or prophylactic agent for immunodeficiency virus infection
US20160130346A1 (en) *	2013-05-29	2016-05-12	Institut National De La Sante Et De La Recherche Medicale	Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
EP3116908B1 (en)	2014-03-14	2019-06-26	Innate Pharma	Humanized kir3dl2 antibodies
WO2018073363A1 (en)	2016-10-21	2018-04-26	Innate Pharma	Treatment with anti-kir3dl2 agents
AU2020210710A1 (en)	2019-01-22	2021-07-29	Innate Pharma	Treatment of T cell lymphoma
KR20230165913A (en)	2021-04-05	2023-12-05	이나뜨 파르마 에스.에이.	Immunohistochemical methods and KIR3DL2-specific reagents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2104526C1 (en) *	1995-05-05	1998-02-10	Эммануил Маркович Коган	Method for diagnosing t-cellular lymphomae of skin
AU1922902A (en) *	2000-12-18	2002-07-01	Inst Nat Sante Rech Med	Novel means for the diagnosis and therapy of CTCL

2001
- 2001-12-18 AU AU1922902A patent/AU1922902A/en active Pending
- 2001-12-18 DK DK01271393.9T patent/DK1343822T3/en active
- 2001-12-18 ES ES01271393T patent/ES2387969T3/en not_active Expired - Lifetime
- 2001-12-18 JP JP2002552015A patent/JP2004528824A/en active Pending
- 2001-12-18 US US10/450,818 patent/US7399595B2/en not_active Expired - Lifetime
- 2001-12-18 WO PCT/EP2001/015417 patent/WO2002050122A2/en not_active Ceased
- 2001-12-18 AU AU2002219229A patent/AU2002219229B2/en not_active Expired
- 2001-12-18 CA CA2432036A patent/CA2432036C/en not_active Expired - Lifetime
- 2001-12-18 EP EP01271393A patent/EP1343822B1/en not_active Expired - Lifetime
- 2001-12-18 AT AT01271393T patent/ATE556092T1/en active
2008
- 2008-03-18 US US12/050,441 patent/US7919085B2/en not_active Expired - Fee Related
- 2008-06-06 JP JP2008149642A patent/JP5134445B2/en not_active Expired - Lifetime
- 2008-06-06 JP JP2008149641A patent/JP2008289489A/en active Pending
2011
- 2011-01-18 US US13/008,406 patent/US8268308B2/en not_active Expired - Fee Related
2012
- 2012-08-15 US US13/585,882 patent/US8518655B2/en not_active Expired - Fee Related

Publication	Publication Date	Title
AU2002219229A1 (en)	2002-09-05	Means for the diagnosis and therapy of CTCL
AUPQ899700A0 (en)	2000-08-17	Probiotic recolonisation therapy
AU2001253411A1 (en)	2001-11-26	Medical dressing assembly and associated method of using the same
AU2001241963A1 (en)	2001-10-15	Improved medical procedure
AU2001233529A1 (en)	2001-08-20	Probiotic therapy for newborns
AU715620C (en)	2001-11-22	Therapeutic methods and uses
AU2002305151A1 (en)	2002-10-21	Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en)	2002-10-21	Gene brcc-3 and diagnostic and therapeutic uses thereof
AU6246199A (en)	2000-04-10	Human interleukin-b50, therapeutic uses
AU2001247841A1 (en)	2001-10-30	Medical procedure
AU2002303261A1 (en)	2002-10-21	Gene brcc2 and diagnostic and therapeutic uses thereof
AU3760400A (en)	2000-10-09	Methods and reagents for the diagnosis and treatment of multiple sclerosis
AU2001293891A1 (en)	2002-04-15	New combination for the treatment of asthma
AU2002227925A1 (en)	2002-05-27	Human beta-defensin-3
AU2002335667A1 (en)	2003-02-17	Modified reoviral therapy
AU2002256053A1 (en)	2002-10-21	Novel bgp compounds for therapy and diagnosis and methods for using same
AU2529799A (en)	1999-08-23	Benzofuran-4-carboxamides and their therapeutic use
AU2002303262A1 (en)	2002-10-21	Gene shinc-1 and diagnostic and therapeutic uses thereof
AU5611701A (en)	2001-10-03	Agent for the diagnosis and therapy of viral diseases
AU2002218977A1 (en)	2002-05-21	Novel marker for the diagnosis and therapy of tumours
AU2002319080A1 (en)	2002-12-09	Method for the diagnosis and therapy of renal cell carcinoma
AU2001292897A1 (en)	2002-04-02	Novel therapy
AU2001253560A1 (en)	2001-10-30	Methods of treatment
AU2001274446A1 (en)	2001-12-17	Vip-related peptides for the treatment of skin disorders
AU2001268903A1 (en)	2001-12-11	Hexaglucal compound and the use and the methods of preparing them